| Structure | Chemical Name | CAS | MF |
|
4-Nitrophenyl 2-O-trans-feruloyl-a-L-arabinofuranoside
|
508220-80-2
|
C21H21NO10
|
|
1H-Pyrazolo[3,4-d]pyrimidine, 3-bromo-1-methyl-6-(methylsulfonyl)-
|
508220-98-2
|
C7H7BrN4O2S
|
|
tert-Butyl 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylcarbamate
|
508223-54-9
|
C18H28BNO4
|
|
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)aniline
|
508223-55-0
|
C13H17BF3NO2
|
|
1,4,5,6-Tetrahydro-cyclopentapyrazol-3-ylaMine
|
508229-66-1
|
C6H9N3
|
|
6-Methyl-1,4,5,6-Tetrahydrocyclopenta[C]Pyrazol-3-Amine(WX609434)
|
508229-68-3
|
C7H11N3
|
|
Cyclopropanecarboxamide, N-(1,4,5,6-tetrahydro-3-cyclopentapyrazolyl)- (9CI)
|
508229-82-1
|
C10H13N3O
|
|
Benzamide, 3-fluoro-N-(1,4,5,6-tetrahydro-3-cyclopentapyrazolyl)- (9CI)
|
508230-01-1
|
C13H12FN3O
|
|
2(1H)-Quinoxalinone,6-amino-1,3-dimethyl-(9CI)
|
508230-24-8
|
C10H11N3O
|
|
Vortioxetine
|
508233-74-7
|
C18H22N2S
|
|
Vortioxetine Impurity 2
|
508233-75-8
|
C18H22N2S
|
|
1-[2-[(2,6-diMethylphenyl)thio]phenyl]- Piperazine
|
508233-76-9
|
C18H22N2S
|
|
Vortioxetine Imp.E
|
508233-77-0
|
C18H22N2S
|
|
Vortioxetine Impurity 3
|
508233-82-7
|
C17H20N2S
|
|
4-[2-(4-methylphenyl)sulfanylphenyl]piperidine
|
508233-95-2
|
C18H21NS
|
|
1H-Indole-5-methanol,-alpha--(aminomethyl)-(9CI)
|
508233-98-5
|
C10H12N2O
|
|
Benzenamine, 2-(3-methyl-1-piperazinyl)- (9CI)
|
508234-01-3
|
C11H17N3
|
|
ethyl 4-(4-(hydroxymethyl)piperidin-1-yl)benzoate
|
508234-07-9
|
C15H21NO3
|
|
N-Biotinyl-N’-(N-Boc-S-trityl)cysteinyl Ethylenediamine
|
508234-94-4
|
C39H49N5O5S2
|
|
1H-Imidazole,1-ethenyl-5-nitro-(9CI)
|
508235-09-4
|
C5H5N3O2
|
|
ethyl 4-oxo-1-propylcyclohexanecarboxylate
|
508235-11-8
|
C12H20O3
|
|
2,3-Difluoro-4-methylphenylboronicacid
|
508235-16-3
|
C7H7BF2O2
|
|
Pyrrolo[1,2-a]pyrazine, octahydro-7-methoxy-, (7R,8aS)- (9CI)
|
508241-13-2
|
C8H16N2O
|
|
Pyrazino[2,1-c][1,4]oxazine, octahydro-, (9aR)- (9CI)
|
508241-14-3
|
C7H14N2O
|
|
2,4-Cyclopentadiene-1-carboxaldehyde,2,5-dichloro-(9CI)
|
508242-23-7
|
C6H4Cl2O
|
|
OroticAcid(VitamineB13)
|
508897-69-9
|
|
|
2,2-Difluorocyclopropylmethanol
|
509072-57-5
|
C4H6F2O
|
|
Cyclopropanemethanol, 2,2-difluoro-3-methyl-, acetate (9CI)
|
509072-65-5
|
C7H10F2O2
|
|
Cyclopropanemethanol, 2,2-difluoro-alpha-methyl-, acetate (9CI)
|
509072-71-3
|
C7H10F2O2
|
|
tert-Butyl 4-(4-nitrobenzoyl)tetrahydro-1(2H)-pyrazinecarboxylate
|
509073-62-5
|
C16H21N3O5
|
|
3-(broMoMethyl)benzaMide
|
509073-67-0
|
C8H8BrNO
|
|
Citric acid Clarithromycin
|
509074-22-0
|
C44H77NO20
|
|
Valdecoxib IMpurity F
|
509074-26-4
|
C16H12ClNO3S
|
|
1H-Imidazole-1-acetaldehyde,alpha-methyl-,oxime,[C(E)]-(9CI)
|
509075-40-5
|
C6H9N3O
|
|
4H-1,2,4-Triazole-4-acetaldehyde,alpha-methyl-,oxime,[C(E)]-(9CI)
|
509075-43-8
|
C5H8N4O
|
|
Ethanol, 2-[2-(2-piperazinyl)ethoxy]- (9CI)
|
509076-90-8
|
C8H18N2O2
|
|
Taiwanhomoflavone B
|
509077-91-2
|
C32H24O10
|
|
catumaxomab
|
509077-98-9
|
|
|
ertumaxomab
|
509077-99-0
|
|
|
4,4'-(2,6-Pyridinediyl)bisbenzaldehyde
|
509078-07-3
|
C19H13NO2
|
|
1β-Hydroxytorilin
|
509078-16-4
|
C22H32O6
|
|
2(3H)-Furanone, dihydro-5-[(3,4,5-trihydroxyphenyl)methyl]- (9CI)
|
509078-28-8
|
C11H12O5
|
|
1,5-Bis-(2,5-dimethyl-thiophen-3-yl)-pentane-1,5-dione
|
509083-57-2
|
C17H20O2S2
|
|
KRP-203
|
509088-69-1
|
C24H27Cl2NO3S
|
|
Benzeneacetonitrile, 2-?chloro-?4-?[(3-?methoxyphenyl)?thio]?-
|
509089-06-9
|
C15H12ClNOS
|
|
Pyridine, 2-methyl-3-propoxy-, 1-oxide (9CI)
|
509090-98-6
|
C9H13NO2
|
|
2-Pyridinemethanol,3-propoxy-(9CI)
|
509090-99-7
|
C9H13NO2
|
|
2-Pyridinecarboxaldehyde,3-(1-methylethoxy)-(9CI)
|
509091-00-3
|
C9H11NO2
|
|
IRAK-1/4 INHIBITOR I
|
509093-47-4
|
C20H21N5O4
|
|
3-Nitro-N-[1-(3-hydroxypropyl)-5-(2,2-dimethylpropionyloxy)-1H-benzimidazol-2-yl]benzamide
|
509093-60-1
|
C22H24N4O6
|
|
1-(4-fluoro-3-nitrobenzyl)piperidine
|
509093-74-7
|
C12H15FN2O2
|
|
N-(1-Phenyl-5-[(piperidin-1-yl)methyl]-1H-benzimidazol-2-yl)-3-nitrobenzamide
|
509093-77-0
|
C26H25N5O3
|
|
N-(1-(3-fluorophenyl)-5-(piperidin-1-ylMethyl)-1H-benzo[d]iMidazol-2-yl)-3-(trifluoroMethyl)benzaMide
|
509093-95-2
|
C27H24F4N4O
|
|
3-fluoro-N-(2-nitro-4-((piperidin-1-yl)methyl)phenyl)benzenamine
|
509093-96-3
|
C18H20FN3O2
|
|
1-(3-Fluorophenyl)-5-[(piperidin-1-yl)methyl]-1H-benzimidazol-2-amine
|
509093-98-5
|
C19H21FN4
|
|
N-[1-(3-Fluorophenyl)-5-[(piperidin-1-yl)Methyl]-1H-benziMidazol-2-yl]-3-nitrobenzaMide
|
509093-99-6
|
C26H24FN5O3
|
|
(4-(cyclohexylamino)-3-nitrophenyl)methanol
|
509094-02-4
|
C13H18N2O3
|
|
4-(cyclohexylamino)-3-nitrobenzaldehyde
|
509094-03-5
|
C13H16N2O3
|
|
N-cyclohexyl-2-nitro-4-((piperidin-1-yl)methyl)benzenamine
|
509094-05-7
|
C18H27N3O2
|
|
1-Cyclohexyl-5-(1-piperidinylmethyl)-1H-benzimidazol-2-amine
|
509094-07-9
|
C19H28N4
|
|
Benzene, 1-(2-methyl-1-propenyl)-2-(trifluoromethyl)- (9CI)
|
509096-19-9
|
C11H11F3
|
|
6-cyclopentyloxy-pyridine-3-carboxylic acid
|
509101-14-8
|
C11H13NO3
|
|
6-(cyclohexyloxy)nicotinic acid
|
509101-15-9
|
C12H15NO3
|
|
Ethyl 4-methyl-2-(methylsulfonyl)pyrimidine-5-carboxylate
|
509101-17-1
|
C9H12N2O4S
|
|
3-Buten-1-ol,4,4-difluoro-3-methyl-,methanesulfonate(9CI)
|
509101-22-8
|
C6H10F2O3S
|
|
2-Pyrimidinecarbonyl chloride, 4,6-dimethoxy- (9CI)
|
509101-33-1
|
C7H7ClN2O3
|
|
2-Benzyl-4-methylpyrimidine-5-carboxylic acid
|
509101-35-3
|
C13H12N2O2
|
|
16,17-Dehydro Capsaicin
|
509101-57-9
|
C18H25NO3
|
|
1,2,3-Benzenetriol, 4-[[[2-(cyclohexyliMino)-4-
|
509102-00-5
|
C17H21N3O3S
|
|
COD.IR.CL.IMES
|
509107-34-0
|
C29H32ClIrN2
|
|
5-Pyrimidinecarboxamide,1,2,3,4-tetrahydro-N,N,6-trimethyl-2-oxo-4-(2-thienyl)-(9CI)
|
509113-66-0
|
C12H15N3O2S
|
|
N-[4-(4-chlorophenoxy)phenyl]-2-[(4-hydroxy-6-propylpyrimidin-2-yl)sulfanyl]acetamide
|
509113-69-3
|
C21H20ClN3O3S
|
|
4-Bromo-2-(trifluoromethoxy)benzoic acid
|
509142-48-7
|
C8H4BrF3O3
|
|
Benzyl [(cis-4-aminocyclohexyl)methyl]carbamate
|
509142-55-6
|
C15H22N2O2
|
|
4-bromo-2-(trifluoromethoxy)phenylacetic acid
|
509142-74-9
|
C9H6BrF3O3
|
|
cis-4-(Boc-aMino)cyclohexaneMethylaMine, 97%
|
509143-00-4
|
C12H24N2O2
|
|
cis-4-(2-aMinoethyl)cyclohexyl]-, 1,1-diMethylethyl ester
|
509143-12-8
|
C13H26N2O2
|
|
2,4-Quinazolinediamine, N2-[cis-4-[[2-[4-bromo-2-(trifluoromethoxy)phenyl]ethyl]amino]cyclohexyl]-N4,N4-dimethyl-
|
509145-82-8
|
C25H29BrF3N5O
|
|
Tert-butyl 4-(methoxymethyl)piperidine-1-carboxylate
|
509147-78-8
|
C12H23NO3
|
|
tert-butyl 4-(2-Methoxyethyl)piperidine-1-carboxylate
|
509147-79-9
|
C13H25NO3
|
|
4-Isobutoxy-piperidine-1-carboxylic acid tert-butyl ester
|
509147-80-2
|
C14H27NO3
|
|
2(3H)-Benzoxazolone,7-fluoro-(9CI)
|
509147-83-5
|
C7H4FNO2
|
|
Ethylene-d4-diamine-1-N-t-Boc
|
509148-73-6
|
H2NCD2CD2NH-t-BOC
|
|
Piperazinone, 6-methyl-3-(1-methylethyl)-, (3S,6S)- (9CI)
|
509149-18-2
|
C8H16N2O
|
|
Bicyclo[2.2.1]hept-5-ene-2-carboxaldehyde, 2,3-dimethyl-, (1R,2R,3R,4S)-rel- (9CI)
|
509149-25-1
|
C10H14O
|
|
Bicyclo[2.2.1]hept-5-ene-2-methanol, 2,3-dimethyl-, (1R,2R,3R,4S)-rel- (9CI)
|
509149-27-3
|
C10H16O
|
|
Bicyclo[2.2.1]hept-5-ene-2-carboxaldehyde, 2,3-dimethyl-, (1S,2S,3S,4R)- (9CI)
|
509149-30-8
|
C10H14O
|
|
Bicyclo[2.2.1]hept-5-ene-2-carboxaldehyde, 2,3-dimethyl-, (1R,2R,3S,4S)- (9CI)
|
509149-31-9
|
C10H14O
|
|
IMidodicarbonic acid, 2-(5-nitro-2-pyridinyl)-, 1,3-bis(1,1-diMethylethyl) ester
|
509150-43-0
|
C15H21N3O6
|
|
BOMBINAKININ M
|
509151-65-9
|
C100H159N31O24
|
|
Ethanol, 2-[(2-fluoro-4-nitrophenyl)amino]- (9CI)
|
509151-97-7
|
C8H9FN2O3
|
|
3-Bromo-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole
|
509152-20-9
|
C10H15BBrNO3
|
|
Ethanone, 1-[2-(2-propenyl)-2H-1,2,3-triazol-4-yl]- (9CI)
|
509953-37-1
|
C7H9N3O
|
|
2H-1,2,3-Triazole-4-carboxylicacid,2-(2-propenyl)-,methylester(9CI)
|
509953-41-7
|
C7H9N3O2
|
|
6-Chloro-N-(4-fluorophenyl)pyridin-3-amine
|
509953-60-0
|
C11H8ClFN2
|
|
2,2-(4-Chloro-6-nitro-1,3-phenylene)diacetic acid
|
510703-81-8
|
C10H8ClNO6
|
|
Methyl 2-(6-chloro-2-oxoindolin-5-yl)acetate
|
510703-84-1
|
C11H10ClNO3
|
|
6-chloro-5-(2-hydroxyethyl)indolin-2-one
|
510703-85-2
|
C10H10ClNO2
|
|
3-Pyridinamine,N-(2-furanylmethyl)-(9CI)
|
510703-88-5
|
C10H10N2O
|
|
trans-Tetrahydro-4-(methylthio)-N-propyl-3-furanamine
|
510707-05-8
|
C8H17NOS
|